Lepidoglyphus destructor allergen (Lep d)

Lepidoglyphus destructor allergen refers to a group of proteins produced by the storage mite Lepidoglyphus destructor, a common inhabitant of stored grain, hay, and damp household environments. These allergens, particularly the major allergen Lep d 2, are significant triggers of IgE-mediated hypersensitivity reactions, including allergic rhinitis, conjunctivitis, and bronchial asthma (PMID: 11030345). Lep d 2 belongs to the Niemann-Pick type C2 (NPC2) protein family and functions as a lipid-binding protein, a characteristic that may contribute to its high allergenicity (UniProt P81528). In clinical practice, these allergens are the primary targets for allergen-specific immunotherapy (AIT), where they are used to induce immunological tolerance in sensitized individuals. The therapeutic mechanism involves shifting the immune response from a Th2-mediated allergic state to a Th1 and regulatory T-cell (Treg) dominated profile, accompanied by the production of blocking IgG4 antibodies (PMID: 30033913). While AIT is effective for long-term symptom relief, the administration of Lepidoglyphus destructor extracts carries a risk of systemic allergic reactions, including anaphylaxis, necessitating careful dose titration and medical supervision (World Allergy Organization).

Other names

Storage mite allergenHay mite allergenLep d 1Lep d 2Lep d 3Lep d 5Lep d 7Lep d 8Lep d 10Lep d 13Glycyphagus destructor allergen

Induction of immune tolerance through allergen-specific immunotherapy (AIT), involving the shift from Th2 to Th1/Treg responses and production of blocking IgG4 antibodies (PMID: 30033913).